Celltrion said it has filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for CT-P42, a biosimilar referencing Eylea (ingredient: aflibercept) for the treatment of ocular diseases.
Based on the global phase 3 results of CT-P42, Celltrion has applied for marketing authorization for all of Eylea's indications, except for pediatric indications such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
In addition to the U.S., the company plans to file for approval of CT-P42 in other key global markets, including Europe.
Celltrion confirmed equivalence and similarity to the Eylea in a phase 3 clinical trial involving 348 patients with diabetic macular edema in 13 countries, including the Czech Republic, Hungary, Poland, and Spain.
"We have confirmed the equivalence and similarity of CT-P42 to Eylea in phase 3 clinical trials and completed the application for marketing authorization with the U.S. FDA," a Celltrion official said. "We will continue to apply for marketing authorization in major countries such as the U.S. and Europe and do our best to expand our biosimilar portfolio in the field of ophthalmic diseases."
Celltrion plans to complete global license applications for up to five biosimilars, including CT-P42, within the year, she added.
Eylea, developed by Regeneron Pharmaceuticals, is a blockbuster ophthalmic treatment that generated global sales of about $9.7 billion last year.
The drug's exclusivity expires in the U.S. in May 2024, and its European substance patent in November 2025.
Related articles
- Celltrion Healthcare rushes to ease worries about its Humira biosimilar
- Celltrion, Jeil Health Science hit by ICURE’s manufacturing violations
- Celltrion to buy back ₩50 billion worth of own stocks for 3rd time this year
- Celltrion's Remsima SC scores marketing authorization in New Zealand
- Celltrion teams up with Rani Therapeutics again to develop oral Humira biosimilar
- Celltrion applies for EMA marketing authorization for Stelara biosimilar
- Celltrion’s Humira biosimilar bags FDA approval to treat autoimmune diseases
- Celltrion’s share buybacks fuel speculation of merger between affiliates
- Celltrion applies for domestic approval for Eylea biosimilar